{"analyses":[{"ciLowerLimit":"0.258","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.552","estimateComment":"The hazard ratios were estimated using Cox regression. The strata were number of prior cancer treatments (1, \\> 1) and β2-microglobulin level (\\< 3.5, ≥ 3.5 mg/L).","groupDescription":"Stratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3134","paramType":"Hazard Ratio (HR)","paramValue":"0.633","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.251","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.468","estimateComment":"The hazard ratios were estimated using Cox regression.","groupDescription":"Unstratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2634","paramType":"Hazard Ratio (HR)","paramValue":"0.608","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI not estimable due to too few events at the time of analysis.","groupId":"OG000","lowerLimit":"15.24","upperLimit":"NA","value":"24.0"},{"comment":"The median duration of overall survival in the BORT + BV arm was not estimable, as too few events had been observed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"description":"Overall survival was defined as the duration of time from randomization until death from any cause. All deaths were included, whether they occurred on study treatment or following treatment discontinuation. Overall survival was estimated using Kaplan-Meier. For patients who had not died, overall survival was censored at the date that the patient was last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.","id":"OG000","title":"BORT + P"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.","id":"OG001","title":"BORT + BV"}],"paramType":"MEDIAN","populationDescription":"Randomized Patients","reportingStatus":"POSTED","timeFrame":"From randomization until death from any cause, up until the end of study (clinical cut-off; up to 116 weeks).","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}